<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-10-05</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39367710/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Mechanisms linking prenatal environment and linear growth: the case of Ramadan during pregnancy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39367710-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Despite established links between prenatal nutritional deprivation and impaired offspring growth, the underlying dynamics and potential moderators remain largely unexplored. This study investigates the dynamics underlying Ramadan during pregnancy and its associations with children&rsquo;s linear growth, using data from the Indonesian Family Life Survey (1993 - 2015). We exploit Ramadan during pregnancy as a natural experiment, separating exposure from maternal background characteristics and season &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAc51FbO1">ğŸ”»ä¿„è¯­çš„æ„æ€æ˜¯ï¼šâ€œä½ è¦å»å“ªï¼Ÿâ€ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oac51fbo1/">
    
    
    
    
    
      
    
    ğŸ”»ä¿„è¯­çš„æ„æ€æ˜¯ï¼šâ€œä½ è¦å»å“ªï¼Ÿâ€ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcAjk9kF">å…¶å®æ­å·çš„é¤é¥®ç»™æˆ‘æœ‰ä¸€ç‚¹å¾ˆæ·±çš„å°è±¡ï¼šç¨å¾®æœ‰ç‚¹åæ°”çš„ï¼Œæ™šä¸Šæ‰“çƒŠä¹Ÿå¤ªæ—©äº†ã€‚ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ªå¤šäº†ã€‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacajk9kf/">
    
    
    
    
    
      
    
    å…¶å®æ­å·çš„é¤é¥®ç»™æˆ‘æœ‰ä¸€ç‚¹å¾ˆæ·±çš„å°è±¡ï¼šç¨å¾®æœ‰ç‚¹åæ°”çš„ï¼Œæ™šä¸Šæ‰“çƒŠä¹Ÿå¤ªæ—©äº†ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ªå¤šäº†ã€‚ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcgJjwPk">ğŸ”»å‡†å¤‡äº†å—ï¼ŸğŸ”»å³ï¼šç¾å†›ä¸­å¤®å¸ä»¤éƒ¨å¸ä»¤ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacgjjwpk/">
    
    
    
    
    
      
    
    ğŸ”»å‡†å¤‡äº†å—ï¼Ÿ<!-- raw HTML omitted -->ğŸ”»å³ï¼šç¾å†›ä¸­å¤®å¸ä»¤éƒ¨å¸ä»¤ã€‚ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcnrvsIg">ğŸ”»F24æ•°æ®æ˜¾ç¤ºï¼šç¾å†› E-3 æ­£åœ¨åœ°ä¸­æµ·ä¸œä¾§é£è¡Œã€‚ğŸ”»ä¸Šæ¬¡åˆºæ€çº³æ–¯é²æ‹‰çš„æ—¶å€™ï¼Œä¹Ÿæ˜¯è¿™æ ·çš„é£è¡Œã€‚#ä¸­ä¸œæ»‘å‘å…¨é¢æˆ˜äº‰# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacnrvsig/">
    
    
    
    
    
      
    
    ğŸ”»F24æ•°æ®æ˜¾ç¤ºï¼šç¾å†› E-3 æ­£åœ¨åœ°ä¸­æµ·ä¸œä¾§é£è¡Œã€‚<!-- raw HTML omitted -->ğŸ”»ä¸Šæ¬¡åˆºæ€çº³æ–¯é²æ‹‰çš„æ—¶å€™ï¼Œä¹Ÿæ˜¯è¿™æ ·çš„é£è¡Œã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¸­ä¸œæ»‘å‘å…¨é¢æˆ˜äº‰#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcqmuNlr">ğŸ”»â€œä¼Šæœ—å¤§å­¦æ˜¯ä¸æ˜¯åªæä¾›ä¸¤ä¸ªå­¦ä½ï¼Ÿ1.å¯¼å¼¹ç”Ÿäº§ï¼Œ2.è§†é¢‘å‰ªè¾‘ï¼Ÿâ€ğŸ”»via vk#ä¸­ä¸œæ»‘å‘å…¨é¢æˆ˜äº‰##çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacqmunlr/">
    
    
    
    
    
      
    
    ğŸ”»â€œä¼Šæœ—å¤§å­¦æ˜¯ä¸æ˜¯åªæä¾›ä¸¤ä¸ªå­¦ä½ï¼Ÿ1.å¯¼å¼¹ç”Ÿäº§ï¼Œ2.è§†é¢‘å‰ªè¾‘ï¼Ÿâ€<!-- raw HTML omitted -->ğŸ”»via vk<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¸­ä¸œæ»‘å‘å…¨é¢æˆ˜äº‰#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çƒ­é—¨è§†é¢‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo.com">https://video.weibo.com</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcx0eMZ1">ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ªå¤šäº†ã€‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacx0emz1/">
    
    
    
    
    
      
    
    ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ªå¤šäº†ã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcyjg0cE">â€¦â€¦å¦‚æœæˆ‘è¯´æˆ‘ä¹°äº†å¥½å‡ åŒ…ç‚¹éƒ½å¾·çš„è¢‹è£…è…Šè‚ ï¼Œä¼šè¢«ç¬‘å—ï¼Ÿ//@LEUNG-wai_bun:[æ€’]ç‚¹éƒ½å¾·å’Œé™¶é™¶å±…åƒäº†å— - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacyjg0ce/">
    
    
    
    
    
      
    
    â€¦â€¦å¦‚æœæˆ‘è¯´æˆ‘ä¹°äº†å¥½å‡ åŒ…ç‚¹éƒ½å¾·çš„è¢‹è£…è…Šè‚ ï¼Œä¼šè¢«ç¬‘å—ï¼Ÿ//<!-- raw HTML omitted -->@LEUNG-wai_bun<!-- raw HTML omitted -->:<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç‚¹éƒ½å¾·å’Œé™¶é™¶å±…åƒäº†å—<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ªå¤šäº†ã€‚ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAcyJxNDU">æ­å·æ€»çš„æ¥è¯´ä¹Ÿè¿˜è¡Œã€‚ä½†æ˜¯è°ˆä¸ä¸Šç‰¹åˆ«å¥½åƒã€‚//@é˜¿ç”°6677:å¹¿å·å¥½åƒæˆ‘çŸ¥é“ï¼Œæ­å·çœŸçš„çœŸçš„éš¾åƒä¹ˆï¼Ÿ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ª...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oacyjxndu/">
    
    
    
    
    
      
    
    æ­å·æ€»çš„æ¥è¯´ä¹Ÿè¿˜è¡Œã€‚ä½†æ˜¯è°ˆä¸ä¸Šç‰¹åˆ«å¥½åƒã€‚//<!-- raw HTML omitted -->@é˜¿ç”°6677<!-- raw HTML omitted -->:å¹¿å·å¥½åƒæˆ‘çŸ¥é“ï¼Œæ­å·çœŸçš„çœŸçš„éš¾åƒä¹ˆï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»å“å¹¿å·çš„é£Ÿç‰©æ¯”æ­å·ç¡®å®å¥½åƒå¤ªå¤šäº†ã€‚ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAeDjCymF">ğŸ”»ä¼Šæœ—å½“å±€ç§°ï¼šç”±äºå†›äº‹æ¼”ä¹ çš„åŸå› ï¼Œå‘å¸ƒé£è¡Œé€šå‘Šï¼ˆNotAMï¼‰ï¼Œä»è€¶è·¯æ’’å†·æ—¶é—´ 10 æœˆ 5 æ—¥ 20 æ—¶ è‡³ 10 æœˆ 9 æ—¥ 4 æ—¶ 30 åˆ†ï¼Œæ¯æ™šå…³é—­è¥¿éƒ¨è¾¹å¢ƒæ²¿çº¿çš„ç©ºä¸­é€šé“ã€‚...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oaedjcymf/">
    
    
    
    
    
      
    
    ğŸ”»ä¼Šæœ—å½“å±€ç§°ï¼šç”±äºå†›äº‹æ¼”ä¹ çš„åŸå› ï¼Œå‘å¸ƒé£è¡Œé€šå‘Šï¼ˆNotAMï¼‰ï¼Œä»è€¶è·¯æ’’å†·æ—¶é—´ 10 æœˆ 5 æ—¥ 20 æ—¶ è‡³ 10 æœˆ 9 æ—¥ 4 æ—¶ 30 åˆ†ï¼Œæ¯æ™šå…³é—­è¥¿éƒ¨è¾¹å¢ƒæ²¿çº¿çš„ç©ºä¸­é€šé“ã€‚<!-- raw HTML omitted -->ğŸ”»via IRNA é€šè®¯ç¤¾<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¸­ä¸œæ»‘å‘å…¨é¢æˆ˜äº‰#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/639b1bfbly1huc4n8riaqj21im1f9kjl.jpg%22">https://tvax3.sinaimg.cn/large/639b1bfbly1huc4n8riaqj21im1f9kjl.jpg&quot;</a> referrerpolicy=&ldquo;no-refer &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OAepBCtmi">ğŸ”»åŠå²›ç”µè§†å°è®°è€…ç§°ï¼Œä»¥å†›å¯¹è´é²ç‰¹å—éƒŠè¿ç»­å‘åŠ¨ç©ºè¢­ã€‚ğŸ”»è®°è€…å·´è¾¾ç»´æŠ¥é“ç§°ï¼Œä»¥è‰²åˆ—è¿ç»­è¢­å‡»è¯¥éƒŠåŒºåå‘ç”Ÿäº†å¼ºçƒˆçˆ†ç‚¸ï¼Œå¹¶è¡¥å……è¯´å…¶ä¸­ä¸€æ¬¡è¢­å‡»é’ˆå¯¹çš„æ˜¯ç¾å›½ç¤¾åŒºã€‚...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oaepbctmi/">
    
    
    
    
    
      
    
    ğŸ”»åŠå²›ç”µè§†å°è®°è€…ç§°ï¼Œä»¥å†›å¯¹è´é²ç‰¹å—éƒŠè¿ç»­å‘åŠ¨ç©ºè¢­ã€‚<!-- raw HTML omitted -->ğŸ”»è®°è€…å·´è¾¾ç»´æŠ¥é“ç§°ï¼Œä»¥è‰²åˆ—è¿ç»­è¢­å‡»è¯¥éƒŠåŒºåå‘ç”Ÿäº†å¼ºçƒˆçˆ†ç‚¸ï¼Œå¹¶è¡¥å……è¯´å…¶ä¸­ä¸€æ¬¡è¢­å‡»é’ˆå¯¹çš„æ˜¯ç¾å›½ç¤¾åŒºã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¸­ä¸œæ»‘å‘å…¨é¢æˆ˜äº‰#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA8UmwqVV">è°å¹²çš„ï¼Ÿè°å¹²çš„ï¼Ÿï¼Ÿï¼Ÿï¼ï¼ - è½¬å‘ @éº¦å½“åŠ³:&amp;ensp;ï¼Ÿï¼Ÿï¼Ÿæ¿çƒ§ä¸‹çº¿äº†ï¼Ÿï¼Ÿï¼Ÿï¼Ÿï¼Ÿ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa8umwqvv/">
    
    
    
    
    
      
    
    è°å¹²çš„ï¼Ÿè°å¹²çš„ï¼Ÿï¼Ÿï¼Ÿï¼ï¼<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@éº¦å½“åŠ³<!-- raw HTML omitted -->:â€‚ï¼Ÿï¼Ÿï¼Ÿæ¿çƒ§ä¸‹çº¿äº†ï¼Ÿï¼Ÿï¼Ÿï¼Ÿï¼Ÿ <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA8X4wLmd">èˆ…èˆ…æŒ‘é€‰äº†è¿™ä¸ªç¾ä¸½çš„åˆåæ•´é¡¿åº—é‡Œçš„å¸ƒå±€æœ¬äººæ²¡æ‹ä¸Šä»€ä¹ˆç”¨åœºå¤§æ¦‚æ˜¯èµ·åˆ°äº†ä¸€ä¸ªè£…é¥°çš„ä½œç”¨</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa8x4wlmd/">
    
    
    
    
    
      
    
    èˆ…èˆ…æŒ‘é€‰äº†è¿™ä¸ªç¾ä¸½çš„åˆåæ•´é¡¿åº—é‡Œçš„å¸ƒå±€<!-- raw HTML omitted -->æœ¬äººæ²¡æ‹ä¸Šä»€ä¹ˆç”¨åœºå¤§æ¦‚æ˜¯èµ·åˆ°äº†ä¸€ä¸ªè£…é¥°çš„ä½œç”¨  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA9b56GWT">çœŸæ˜¯è¶Šé•¿å¤§è¶Šè§‰å¾—æˆ‘çˆ¹æœ‰ç—…</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa9b56gwt/">
    
    
    
    
    
      
    
    çœŸæ˜¯è¶Šé•¿å¤§è¶Šè§‰å¾—æˆ‘çˆ¹æœ‰ç—…  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA9eLnIiC">è¿‡å¹´çš„æ—¶å€™å®¶é‡Œåµäº†å¥½å‡ æ¶æˆ‘çˆ¹æƒ³ç€æ³•è·Ÿæˆ‘è¯´æ•™è¿˜æŒ‘æ‹¨ç¦»é—´ä¸Šäº†è¯´æˆ‘è·Ÿæˆ‘å§å§å¦¹å¦¹ç°åœ¨è¦å¥½éƒ½æ˜¯å‡çš„è¦å¥½ä»¥åç»“å©šäº†è¿˜è¿™æ ·æ¯å¤©åœ¨ä¸€èµ·æ‰æ˜¯çœŸçš„å¥½ç„¶ååˆè¯´ä½ ä»¬æ•´å¤©åœ¨ä¸€èµ·...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa9elniic/">
    
    
    
    
    
      
    
    è¿‡å¹´çš„æ—¶å€™å®¶é‡Œåµäº†å¥½å‡ æ¶<!-- raw HTML omitted -->æˆ‘çˆ¹æƒ³ç€æ³•è·Ÿæˆ‘è¯´æ•™è¿˜æŒ‘æ‹¨ç¦»é—´ä¸Šäº†<!-- raw HTML omitted -->è¯´æˆ‘è·Ÿæˆ‘å§å§å¦¹å¦¹ç°åœ¨è¦å¥½éƒ½æ˜¯å‡çš„è¦å¥½<!-- raw HTML omitted -->ä»¥åç»“å©šäº†è¿˜è¿™æ ·æ¯å¤©åœ¨ä¸€èµ·æ‰æ˜¯çœŸçš„å¥½<!-- raw HTML omitted -->ç„¶ååˆè¯´ä½ ä»¬æ•´å¤©åœ¨ä¸€èµ·ä¹Ÿä¸è¡Œä½ ä»¬è€å…¬ä¼šç”Ÿæ°”çš„<!-- raw HTML omitted -->ï¼ˆæƒ¹é‚£ä¸ªæ—¶å€™å°±çŸ¥é“ä»–ä¸å–œæ¬¢å¦ˆå¦ˆå¤©å¤©è·Ÿå¥¹å¨˜å®¶äººåœ¨ä¸€èµ·ä»–è‡ªå·±ç ´é˜²äº†ï¼‰<!-- raw HTML omitted -->åæ­£å°±æ˜¯äººæ— è¯­çš„æ—¶å€™çœŸçš„ä¼šç¬‘  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OAa8esK7H">ä¸Šä¸ªbç­éšæœºè¢«å¤§äººå“æ­»ä»Šæ™šç®—é’±æˆ‘é‚£å°æœºå­å°‘äº†ä¸€åƒå…­æ€»æ•°åŠ èµ·æ¥åˆå°‘äº”ç™¾å¤šä¸‰ä¸ªäººä¸ä¿¡é‚ªç®—äº†ä¸€éåˆä¸€éæœ€ç»ˆè¿˜æ˜¯å·®é’±åƒé¥­çš„æ—¶å€™ä¸‰ä¸ªå¤§äººï¼ˆå››ä¸ªäººåƒé¥­è¿˜æœ‰ä¸ªæˆ‘èˆ…ï¼‰...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oaa8esk7h/">
    
    
    
    
    
      
    
    ä¸Šä¸ªbç­éšæœºè¢«å¤§äººå“æ­»<!-- raw HTML omitted -->ä»Šæ™šç®—é’±æˆ‘é‚£å°æœºå­å°‘äº†ä¸€åƒå…­<!-- raw HTML omitted -->æ€»æ•°åŠ èµ·æ¥åˆå°‘äº”ç™¾å¤š<!-- raw HTML omitted -->ä¸‰ä¸ªäººä¸ä¿¡é‚ªç®—äº†ä¸€éåˆä¸€éæœ€ç»ˆè¿˜æ˜¯å·®é’±<!-- raw HTML omitted -->åƒé¥­çš„æ—¶å€™ä¸‰ä¸ªå¤§äººï¼ˆå››ä¸ªäººåƒé¥­è¿˜æœ‰ä¸ªæˆ‘èˆ…ï¼‰<!-- raw HTML omitted -->ä¸€èµ·å¤ç›˜ï¼Œä¸çŸ¥é“å“ªé‡Œå‡ºäº†å·®é”™ï¼Œå”ä¼¯ä¹Ÿé—®æˆ‘æœ‰æ²¡æœ‰ä¹°ä»€ä¹ˆä¸œè¥¿æœ‰æ²¡æœ‰äººæ‹¿ç€å•å­æ¥æ‰¾æˆ‘æˆ‘è¯´æ²¡æœ‰<!-- raw HTML omitted -->ç„¶åæˆ‘èˆ…çªç„¶è¯´<!-- raw HTML omitted -->æ˜¯ä¸æ˜¯ä¹‹å‰å“ªä¸ªå­¦æ ¡çš„å•å­æ­£å¥½æ˜¯ä¸€åƒå…­<!-- raw HTML omitted -->æˆ‘éš”å£çš„ä¼¯ä¼¯è¯´è¿˜çœŸæœ‰è¿™ä¸ªå•å­æ²¡æ’•èµ·æ¥<!-- raw HTML omitted -->ä½†æ˜¯ä¸ç¡®å®šè¿™é’±è¿›å¸æˆ·äº†æ²¡<!-- raw HTML omitted --><!-- raw HTML omitted -->å¦ˆçš„å“æ­»æˆ‘äº†æˆ‘éƒ½æƒ³å¥½æ‹¿æˆ‘å·¥èµ„å»å¡«è¿™ä¸€åƒå…­äº† &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OAbrDkcYr">ç¦»å©šï¼ŒçœŸçš„ - è½¬å‘ @éº¦å½“åŠ³:&amp;ensp;å¦‚æœæœ‰å¤©æ¿çƒ§ä¸‹æ¶äº†ï¼Œä½ ä¼š____ã€‚#æ·±å¤œå¼€éº¦# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oabrdkcyr/">
    
    
    
    
    
      
    
    ç¦»å©šï¼ŒçœŸçš„<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@éº¦å½“åŠ³<!-- raw HTML omitted -->:â€‚å¦‚æœæœ‰å¤©æ¿çƒ§ä¸‹æ¶äº†ï¼Œä½ ä¼š____ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->#æ·±å¤œå¼€éº¦#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OAbrrDJom">æ´—æ¾¡æ´—ä¸€åŠæ²¡çƒ­æ°´äº†ï¼Œç°åœ¨è‚šå­å†°å†°çš„[ä¸¾è½¦]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oabrrdjom/">
    
    
    
    
    
      
    
    æ´—æ¾¡æ´—ä¸€åŠæ²¡çƒ­æ°´äº†ï¼Œç°åœ¨è‚šå­å†°å†°çš„<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OAbwzBPcW">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ via.ç·’è¡Œè®°fb [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oabwzbpcw/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ç·’è¡Œè®°fb &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/006z6nxLgy1hubmroaqncj30u00k0410.jpg%22">https://tvax2.sinaimg.cn/large/006z6nxLgy1hubmroaqncj30u00k0410.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OAeT62nJc">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.10.01 15:26(è¡¥)ã€Œå“Ÿã€å¿ƒæƒ…æ„‰å¿«ä»Šå¤©æ„Ÿè§‰èƒ½æ—¶éš”è®¸ä¹…åœ°ç¡ä¸ªå¥½è§‰ï¼Œä¹Ÿæ„Ÿè§‰ç§‹å¤©çš„è¡£æœä¸å¤Ÿç”¨äº†...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oaet62njc/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?cont">https://m.weibo.cn/search?cont</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OAeTdolKs">[äº²äº²][äº²äº²][äº²äº²] - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.10.01 15:30(è¡¥)ã€Œæ¬¸å˜¿å˜¿ã€&lt;å›¾&gt;è¯´èµ·æ¥æ—©å‰è·Ÿå¥½å–œæ¬¢å¥½å–œæ¬¢çš„æœ‹å‹è§é¢å•¦â˜ºï¸æ—¶éš”...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oaetdolks/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OA9tep0XX">ä¹…ä¿å²ç»ªé‡Œ via.ç·’è¡Œè®°fb [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oa9tep0xx/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ç·’è¡Œè®°fb <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OAcFmwf82">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.10.01 15:26(è¡¥)ã€Œå“Ÿã€å¿ƒæƒ…æ„‰å¿«ä»Šå¤©æ„Ÿè§‰èƒ½æ—¶éš”è®¸ä¹…åœ°ç¡ä¸ªå¥½è§‰ï¼Œä¹Ÿæ„Ÿè§‰ç§‹å¤©çš„è¡£æœä¸å¤Ÿç”¨äº†ã€ã€ã€æ„Ÿè§‰ä¸å¿…å¿ƒæ€¥ã€ã€ä½†ä¹Ÿæ„Ÿè§‰æœ‰...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oacfmwf82/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OAcHBFG3A">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.10.01 15:30(è¡¥)ã€Œæ¬¸å˜¿å˜¿ã€&lt;å›¾&gt;è¯´èµ·æ¥æ—©å‰è·Ÿå¥½å–œæ¬¢å¥½å–œæ¬¢çš„æœ‹å‹è§é¢å•¦â˜ºï¸æ—¶éš”è®¸ä¹…èƒ½æœ‰è¿™æ ·çš„æ—¶å…‰èŠäº†å¾ˆå¤šï¼Œè®©æˆ‘å¿ƒæƒ…å¾ˆé«˜å…´...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oachbfg3a/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpa">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpa</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363334/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">Consensus statements for the establishment of medical intensive care in low-resource settings: international study using modified Delphi methodology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363334-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Delphi process identified a set of consensus-based statements on how to create a sustainable patient-centered medical intensive care in &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363334/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Consensus statements for the establishment of medical intensive care in low-resource settings: international study using modified Delphi methodology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363334-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Delphi process identified a set of consensus-based statements on how to create a sustainable patient-centered medical intensive care in &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363441/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">Systematic review of environmental noise in neonatal intensive care units</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363441-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: All NICUs exceeded recommended accumulative sound levels. People were the most consistent source of noise. Sound pressure levels need to be consistently measured with devices adhering to international SLM standards in future &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363441/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Systematic review of environmental noise in neonatal intensive care units</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363441-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: All NICUs exceeded recommended accumulative sound levels. People were the most consistent source of noise. Sound pressure levels need to be consistently measured with devices adhering to international SLM standards in future &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363862/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/hypomethylating agents</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363862-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patients had concurrent bone marrow involvement. Twenty (43%) patients had highrisk genetic features according to the European Leukemia Net 2022 classification. Twenty-nine (63%) were relapsed or refractory after intensive chemotherapy (CTX) including 13 (28%) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363862/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/hypomethylating agents</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363862-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patients had concurrent bone marrow involvement. Twenty (43%) patients had highrisk genetic features according to the European Leukemia Net 2022 classification. Twenty-nine (63%) were relapsed or refractory after intensive chemotherapy (CTX) including 13 (28%) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363864/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20241004202124&amp;v=2.18.0.post9&#43;e462414">Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363864-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20241004202124-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi, in patients with R/R B-cell malignancies (NCT03740529). Pirtobrutinib was investigated in 127 patients with intolerance to at least one prior BTKi therapy in the absence of progressive disease. The most common adverse event (AE) leading to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363864/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20241005190856&amp;v=2.18.0.post9&#43;e462414">Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363864-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20241005190856-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi, in patients with R/R B-cell malignancies (NCT03740529). Pirtobrutinib was investigated in 127 patients with intolerance to at least one prior BTKi therapy in the absence of progressive disease. The most common adverse event (AE) leading to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363890/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">Exploring public cancer gene expression signatures across bulk, single-cellÂ and spatial transcriptomics data with signifinder Bioconductor package</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363890-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Understanding cancer mechanisms, defining subtypes, predicting prognosis and assessing therapy efficacy are crucial aspects of cancer research. Gene-expression signatures derived from bulk gene expression data have played a significant role in these endeavors over the past decade. However, recent advancements in high-resolution transcriptomic technologies, such as single-cell RNA sequencing and spatial transcriptomics, have revealed the complex cellular heterogeneity within tumors, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39363890/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Exploring public cancer gene expression signatures across bulk, single-cellÂ and spatial transcriptomics data with signifinder Bioconductor package</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39363890-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Understanding cancer mechanisms, defining subtypes, predicting prognosis and assessing therapy efficacy are crucial aspects of cancer research. Gene-expression signatures derived from bulk gene expression data have played a significant role in these endeavors over the past decade. However, recent advancements in high-resolution transcriptomic technologies, such as single-cell RNA sequencing and spatial transcriptomics, have revealed the complex cellular heterogeneity within tumors, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365164/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">A Remote Patient Monitoring System with Feedback Mechanisms using a Smartwatch: Concept, Implementation and Evaluation based on the activeDCM Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365164-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our results mark a first step towards integrating RPM systems, based on a consumer wearable device for primary patient input, into standardized clinical workflows. They can serve as a blueprint for creating a user-friendly, reusable, interoperable and secure RPM system, that can be integrated into patients' daily &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365164/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">A Remote Patient Monitoring System with Feedback Mechanisms using a Smartwatch: Concept, Implementation and Evaluation based on the activeDCM Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365164-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our results mark a first step towards integrating RPM systems, based on a consumer wearable device for primary patient input, into standardized clinical workflows. They can serve as a blueprint for creating a user-friendly, reusable, interoperable and secure RPM system, that can be integrated into patients' daily &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365172/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">Association of circulating fatty acids with cardiovascular disease risk: Analysis of individual-level data in three large prospective cohorts and updated meta-analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365172-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our study provides an overview of the most recent evidence on the associations between objectively measured FAs and CVD outcomes. Collectively, the data reveals notable differences in associations by SFA subtypes and calls for further studies, especially RCTs, to explore these &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365172/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Association of circulating fatty acids with cardiovascular disease risk: Analysis of individual-level data in three large prospective cohorts and updated meta-analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365172-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our study provides an overview of the most recent evidence on the associations between objectively measured FAs and CVD outcomes. Collectively, the data reveals notable differences in associations by SFA subtypes and calls for further studies, especially RCTs, to explore these &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365257/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241004202134&amp;v=2.18.0.post9&#43;e462414">Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365257-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241004202134-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365257/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241005190913&amp;v=2.18.0.post9&#43;e462414">Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365257-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241005190913-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365257/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20241004202124&amp;v=2.18.0.post9&#43;e462414">Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365257-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20241004202124-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365257/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20241005190856&amp;v=2.18.0.post9&#43;e462414">Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365257-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20241005190856-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365479/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241004202135&amp;v=2.18.0.post9&#43;e462414">Single mandibular implant study - impact on dietary habits after 5 years of observation in patients with immediate and delayed loading protocols</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365479-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241004202135-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: A change in the patients' dietary habits due to the insertion of a single midline implant in the mandible to support the existing complete denture cannot be observed, independently to the loading &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39365479/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Single mandibular implant study - impact on dietary habits after 5 years of observation in patients with immediate and delayed loading protocols</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39365479-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: A change in the patients' dietary habits due to the insertion of a single midline implant in the mandible to support the existing complete denture cannot be observed, independently to the loading &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366356/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Exploring the expanding universe of host-virus interactions mediated by viral RNA</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366356-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    RNA is a central molecule in RNA virus biology; however, the interactions that it establishes with the host cell are only starting to be elucidated. In recent years, a methodology revolution has dramatically expanded the scope of host-virus interactions involving the viral RNA (vRNA). A second wave of method development has enabled the precise study of these protein-vRNA interactions in a life cycle stage-dependent manner, as well as providing insights into the interactome of specific &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366358/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Let&#39;s get functional: Drug sensitivity profiling to enable precision sarcoma medicine</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366358-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Drug sensitivity profiling in patient-derived tumor models offers new hope for improving outcomes in cancers lacking effective therapies. Al Shihabi et al.Â¹ demonstrate that short-term cultures from bone and soft tissue sarcomas enable clinically meaningful screening of multiple drugs and combinations, marking a significant advance in personalized care for these high-risk &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366373/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Spark in the darkness: Discovering action potentials in brain tumors</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366373-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Gliomas exhibit significant molecular diversity and poor prognosis. In this issue of Cancer Cell, Curry et al. apply Patch-seq on human glioma samples uncovering hybrid cells with glial and neuronal features, capable of firing action potentials in isocitrate dehydrogenase mutant gliomas. These findings highlight the importance of neural features in tumor biology and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366504/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Small-molecule mediated MuRF1 Inhibition protects from Doxorubicin-induced Cardiac Atrophy and Contractile Dysfunction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366504-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cancer chemotherapy induces cell stress in rapidly dividing cancer cells to trigger their growth arrest and apoptosis. However, adverse effects related to cardiotoxicity underpinned by a limited regenerative potential of the heart limits clinical application: In particular, chemotherapy with doxorubicin (DOXO) causes acute heart injury that can transition to persisting cardiomyopathy (DOXO-CM). Here, we tested if MuRF1 inhibition (&ldquo;MuRFi&rdquo;) was able to attenuate DOXO-CM. To mimic &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366628/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Evaluation of antioxidant and anti-inflammatory properties of Lacticaseibacillus rhamnosus Ram12-derived exopolysaccharide in a D-galactose-induced liver injury mouse model</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366628-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We investigated the antioxidant and anti-inflammatory properties of Lacticaseibacillus rhamnosus Ram12-derived EPSRam12 in a D-galactose-induced liver injury mouse model. Initially, EPSRam12 was characterized for its composition, molecular weight, and structural features. It was then administered orally to D-galactose-induced mice (which had received an intraperitoneal injection of D-galactose, 100 mg/kg body weight) at doses of 25 mg/kg (low dose) and 50 mg/kg (high dose) for 45 days. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366729/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366729-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Smoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4Â·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and although strategies have recently been proposed to achieve tobacco-free generations, none have been implemented to date. Assessing what could happen if current trends in smoking prevalence persist, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366729/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20241005190856&amp;v=2.18.0.post9&#43;e462414">Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366729-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20241005190856-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Smoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4Â·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and although strategies have recently been proposed to achieve tobacco-free generations, none have been implemented to date. Assessing what could happen if current trends in smoking prevalence persist, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366734/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20241005190856&amp;v=2.18.0.post9&#43;e462414">Systematic literature review of published cases of reactive plasmacytosis in peripheral blood and bone marrow</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366734-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20241005190856-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with an increase in the number and/or proportion of plasma cells in peripheral blood and/or bone marrow, clinical context and a broad differential diagnosis are necessary to direct further evaluation and arrive at a correct diagnosis. Our literature review suggests that evaluation for infectious causes and AITL may be of the greatest yield in many &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366918/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Unveiling the Complexity of cis-Regulation Mechanisms in Kinases: A Comprehensive Analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366918-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Protein cis-regulatory elements (CREs) are regions that modulate the activity of a protein through intramolecular interactions. Kinases, pivotal enzymes in numerous biological processes, often undergo regulatory control via inhibitory interactions in cis. This study delves into the mechanisms of cis regulation in kinases mediated by CREs, employing a combined structural and sequence analysis. To accomplish this, we curated an extensive dataset of kinases featuring annotated CREs, organized &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39366943/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Author Correction: Compartments in medulloblastoma with extensive nodularity are connected through differentiation along the granular precursor lineage</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39366943-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39367019/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Patterns of intersectional tumor volumes in T2-weighted MRI and [&lt;sup&gt;18&lt;/sup&gt;F]FET PET in adult glioma: a prospective, observational study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39367019-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Brain tumor volumes as assessed by magnetic resonance imaging (MRI) do not always spatially overlap with biological tumor volumes (BTV) measured by [^(18)F]Fluoroethyltyrosine positron emission tomography ([^(18)F]FET PET). We prospectively investigated volumetric patterns based on the extent of tumor volume overlap between the two modalities. Eighty-six patients with newly diagnosed glioma who had undergone MRI and [^(18)F]FET PET between 2007 and 2009 were included in this prospective &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39367058/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Author Correction: High-resolution mapping of urban Aedes aegypti immature abundance through breeding site detection based on satellite and street view imagery</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39367058-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39367487/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241005190914&amp;v=2.18.0.post9&#43;e462414">Revisiting the scope and expectations of Implementation Science and Implementation Science Communications</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39367487-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241005190914-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    This editorial updates the scope and submission expectations of Implementation Science and Implementation Science Communications. We refine our protocol publishing policies and set out new expectations for reporting studies describing determinants and their relationship with implementation outcomes. Our central focus remains on the implementation of evidence-based interventions into healthcare practice and policy. We are most interested in rigorous empirical studies of the implementation &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OzXuQr2ML">ä»Šå¤©WaPo Podcastâ€”Post Reportsè¯·äº†è¯¥æœºæ„è´Ÿè´£é€‰ä¸¾æ°‘è°ƒï¼ˆpollï¼‰å‰¯ä¸»ä»»Emily Guskinç§‘æ™®äº†2024å¹´å¤§é€‰æ°‘è°ƒã€‚æœ‰ä¸¤ç‚¹å¾ˆæœ‰æ„æ€ã€‚ç¬¬ä¸€å°±æ˜¯è·Ÿæˆ‘çŒœæƒ³å¾—ä¸€æ ·ï¼Œ2024å¹´å¤§é€‰...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-ozxuqr2ml/">
    
    
    
    
    
      
    
    ä»Šå¤©WaPo Podcastâ€”Post Reportsè¯·äº†è¯¥æœºæ„è´Ÿè´£é€‰ä¸¾æ°‘è°ƒï¼ˆpollï¼‰å‰¯ä¸»ä»»Emily Guskinç§‘æ™®äº†2024å¹´å¤§é€‰æ°‘è°ƒã€‚æœ‰ä¸¤ç‚¹å¾ˆæœ‰æ„æ€ã€‚ç¬¬ä¸€å°±æ˜¯è·Ÿæˆ‘çŒœæƒ³å¾—ä¸€æ ·ï¼Œ2024å¹´å¤§é€‰pollç»Ÿè®¡æ–¹æ³•æ˜¯è¿›è¡Œäº†è°ƒæ•´äº†çš„ã€‚Pollsteræ¯å¹´çš„å¤§ä¼šAAPCä¼šè®¨è®ºæ›´æ–°ç»Ÿè®¡å­¦æŠ½æ ·æ–¹æ³•ä»¥å»é™¤åå€šï¼Œ2024å¤§é€‰æœ€é‡è¦çš„æ˜¯è°ƒæ•´å—æ•™è‚²ç¨‹åº¦é«˜å’Œâ€œä¸å“åº”â€pollä¸¤ä¸ªäººç¾¤çš„æ¯”é‡ï¼Œä»¥è®©pollç»“æœæ›´æ¥è¿‘æ™®é€šäººç¾¤ï¼Œä½†æˆ‘è§‰å¾—è¿™æ ·è°ƒæ•´åçš„ç»“æœå‡ºç°äº†å¾ˆå¤šåå¸¸è¯†çš„ç°è±¡ï¼Œæ¯”å¦‚NYT/Siena pollä¼šå‡ºç°å¹´è½»æˆ–è€…å¥³æ€§é€‰æ°‘å¤§é‡æ”¯æŒRçš„æƒ…å†µã€‚ç¬¬äºŒå°±æ˜¯Guskiné¼“åŠ±æ™®é€šäººå»è¯»pollçš„æ–¹æ³•å­¦ã€‚å¥¹è®¤ä¸ºè¶Šæ˜¯å…¬å¸ƒè¯¦ç»†æ–¹æ³•å­¦çš„pollè¶Šå¯é ï¼Œè¿™ç‚¹æˆ‘å¾ˆè®¤å¯ã€‚å¥½çš„polléå¸¸ç§‘å­¦å®¢è§‚ï¼Œè€Œå·®çš„pollå…·æœ‰å¼ºçƒˆçš„è¯±å¯¼æ€§ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E7%25B">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E7%B</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OzYRpFP9e">çœ‹ä¸´åºŠè¯•éªŒçš„TEAEï¼Œå‡ ç™¾é¡µï¼Œç»†è‡´åˆ°æ¯ä¸ªç—‡çŠ¶å’Œä½“å¾ï¼Œè¦æŠŠè¿™äº›ç—‡çŠ¶å’Œä½“å¾æŒ‰ç…§ä¸´åºŠåˆ†ç§‘è¿›è¡Œåˆ†é—¨åˆ«ç±»ï¼Œè¿™æ—¶å°±æ˜¯è€ƒå¯Ÿä¸´åºŠçŸ¥è¯†çš„æ—¶åˆ»äº†ï¼Œæ¯”å¦‚ï¼ŒCellulitisæˆ–Osteomyeli...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-ozyrpfp9e/">
    
    
    
    
    
      
    
    çœ‹ä¸´åºŠè¯•éªŒçš„TEAEï¼Œå‡ ç™¾é¡µï¼Œç»†è‡´åˆ°æ¯ä¸ªç—‡çŠ¶å’Œä½“å¾ï¼Œè¦æŠŠè¿™äº›ç—‡çŠ¶å’Œä½“å¾æŒ‰ç…§ä¸´åºŠåˆ†ç§‘è¿›è¡Œåˆ†é—¨åˆ«ç±»ï¼Œè¿™æ—¶å°±æ˜¯è€ƒå¯Ÿä¸´åºŠçŸ¥è¯†çš„æ—¶åˆ»äº†ï¼Œæ¯”å¦‚ï¼ŒCellulitisæˆ–Osteomyelitisæ˜¯å“ªä¸ªç§‘å®¤çš„ä¸´åºŠè¡¨ç°ï¼ŸRhabdomyolysisæ˜¯å“ªä¸ªä¸“ç§‘çš„ä¸´åºŠè¡¨ç°ï¼ŸSciaticaæ˜¯å“ªä¸ªä¸“ç§‘ä¸´åºŠè¡¨ç°ï¼ŸForeign body aspirationåº”è¯¥å»å“ªä¸ªç§‘å®¤ï¼Ÿ  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA2AdA70h">ğŸ”»Planet Labs å«æ˜Ÿå›¾åƒæ˜¾ç¤ºå†…ç“¦æå§†ç©ºå†›åŸºåœ°çš„ F-35 æ©ä½“å’Œå¦ä¸€åº§å»ºç­‘é­åˆ°è¢­å‡»ã€‚ğŸ”»F-35 æ©ä½“å¤©çµç›–è¢«å¼€äº†æ´ã€‚#ä¼Šæœ—ä»¥è‰²åˆ—å†›äº‹åŠ›é‡å¯¹æ¯”# [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa2ada70h/">
    
    
    
    
    
      
    
    ğŸ”»Planet Labs å«æ˜Ÿå›¾åƒæ˜¾ç¤ºå†…ç“¦æå§†ç©ºå†›åŸºåœ°çš„ F-35 æ©ä½“å’Œå¦ä¸€åº§å»ºç­‘é­åˆ°è¢­å‡»ã€‚<!-- raw HTML omitted -->ğŸ”»F-35 æ©ä½“å¤©çµç›–è¢«å¼€äº†æ´ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¼Šæœ—ä»¥è‰²åˆ—å†›äº‹åŠ›é‡å¯¹æ¯”#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;img &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA2BLcT00">ğŸ”»ä»¥å†›å®˜ç½‘è¦æ±‚ä»¥è‰²åˆ—äººä¸è¦ä¸Šä¼ ä»»ä½•æ¥è‡ªæŠµæŠ—ä¹‹å¼§çš„è¢­å‡»æ•ˆæœè§†é¢‘ç…§ç‰‡ã€‚ğŸ”»å¿«è¿›åˆ°å­¦SBUæŠ“äººã€‚#ä¼Šæœ—ä»¥è‰²åˆ—å†›äº‹åŠ›é‡å¯¹æ¯”# [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa2blct00/">
    
    
    
    
    
      
    
    ğŸ”»ä»¥å†›å®˜ç½‘è¦æ±‚ä»¥è‰²åˆ—äººä¸è¦ä¸Šä¼ ä»»ä½•æ¥è‡ªæŠµæŠ—ä¹‹å¼§çš„è¢­å‡»æ•ˆæœè§†é¢‘ç…§ç‰‡ã€‚<!-- raw HTML omitted -->ğŸ”»å¿«è¿›åˆ°å­¦SBUæŠ“äººã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¼Šæœ—ä»¥è‰²åˆ—å†›äº‹åŠ›é‡å¯¹æ¯”#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA2EG088e">ğŸ”»ä¹‹å‰ï¼Œä»¥è‰²åˆ—å¨èƒè¯´ï¼šâ€œå¦‚æœä»»ä½•ä¼Šæœ—é£æœºé™è½åœ¨è´é²ç‰¹æœºåœºï¼Œæˆ‘ä»¬å°†æ‘§æ¯è¯¥é£æœºå’Œæœºåœºã€‚â€ğŸ”»ä»Šå¤©ï¼Œä¼Šæœ—å¤–é•¿äº²è‡ªå¸¦é¢†ä¼Šæœ—èˆªç­ç€é™†è´é²ç‰¹ã€‚ğŸ”»è¿˜æ˜¯å¾ˆå‹‡çš„ã€‚#...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa2eg088e/">
    
    
    
    
    
      
    
    ğŸ”»ä¹‹å‰ï¼Œä»¥è‰²åˆ—å¨èƒè¯´ï¼šâ€œå¦‚æœä»»ä½•ä¼Šæœ—é£æœºé™è½åœ¨è´é²ç‰¹æœºåœºï¼Œæˆ‘ä»¬å°†æ‘§æ¯è¯¥é£æœºå’Œæœºåœºã€‚â€<!-- raw HTML omitted -->ğŸ”»ä»Šå¤©ï¼Œä¼Šæœ—å¤–é•¿äº²è‡ªå¸¦é¢†ä¼Šæœ—èˆªç­ç€é™†è´é²ç‰¹ã€‚<!-- raw HTML omitted -->ğŸ”»è¿˜æ˜¯å¾ˆå‹‡çš„ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¼Šæœ—ä»¥è‰²åˆ—å†›äº‹åŠ›é‡å¯¹æ¯”#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E7%83%AD%E9%97%A8%E8%A7%86%E9%A2%259">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E7%83%AD%E9%97%A8%E8%A7%86%E9%A2%9</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA2OouqEX">ğŸ”»ä¸€ä¸ªç¾å›½ç½‘å‹è¯´ï¼šâ€œæˆ‘ç®€ç›´ä¸æ•¢ç›¸ä¿¡ä»Šå¤©çœ‹åˆ°çš„ä¸€åˆ‡ã€‚æˆ‘å·²ç»åœ¨å¤–å¥”æ³¢äº† 12 ä¸ªå°æ—¶ï¼Œä¸ºå±±åŒºçš„äººä»¬è¿é€ç‰©èµ„ã€‚æˆ‘å»è¿‡æ¨è¥¿å¿ã€ç±³åˆ‡å°”å¿ã€è´å…‹æ–¯ç»´å°”ã€æ–¯æ™®é²æ–¯æ´¾æ©...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa2oouqex/">
    
    
    
    
    
      
    
    ğŸ”»ä¸€ä¸ªç¾å›½ç½‘å‹è¯´ï¼šâ€œæˆ‘ç®€ç›´ä¸æ•¢ç›¸ä¿¡ä»Šå¤©çœ‹åˆ°çš„ä¸€åˆ‡ã€‚æˆ‘å·²ç»åœ¨å¤–å¥”æ³¢äº† 12 ä¸ªå°æ—¶ï¼Œä¸ºå±±åŒºçš„äººä»¬è¿é€ç‰©èµ„ã€‚æˆ‘å»è¿‡æ¨è¥¿å¿ã€ç±³åˆ‡å°”å¿ã€è´å…‹æ–¯ç»´å°”ã€æ–¯æ™®é²æ–¯æ´¾æ©ã€ä¼¯æ©æ–¯ç»´å°”ç­‰åœ°ã€‚æˆ‘è®©ä¸€ä½è€äººç»§ç»­ä½¿ç”¨å‘ç”µæœºä¾›æ°§ï¼Œå¹¶é™ªä»–ç­‰åˆ°å®¶äººå‡ºç°ã€‚æˆ‘å‘äººä»¬å‘æ”¾äº†æ•°åƒç¾å…ƒã€‚ä»–ä»¬æ²¡æœ‰è·¯ï¼Œæ²¡æœ‰ç”µåŠ›ï¼Œæ²¡æœ‰é£Ÿç‰©ã€‚äººä»¬å¥„å¥„ä¸€æ¯ã€‚å¤§ç”·äººä»¬å“­ç€æ‹¥æŠ±æˆ‘ï¼Œå› ä¸ºæˆ‘ç»™äº†ä»–ä»¬100ç¾å…ƒã€‚æˆ‘æ˜å¤©è¿˜è¦å†å»å‘ä¸€æ¬¡ã€‚ä»Šå¤©çš„æ‰€è§æ‰€é—»è®©æˆ‘æ„Ÿåˆ°æ¶å¿ƒï¼Œæˆ‘ä¹Ÿæ–­æ–­ç»­ç»­å“­äº†ä¸€æ•´å¤©ï¼Œæˆ‘é€šå¸¸ä¸ä¼šè¿™æ ·ã€‚ç¾å›½æ”¿åºœåœ¨å°åŸé•‡çš„æŠ•æ”¾ç‚¹æ²¡æ”¶ç‰©èµ„ï¼Œè¿™å°±æ˜¯ä¸ºä»€ä¹ˆæˆ‘è¦æŠŠæ‰€æœ‰ä¸œè¥¿ç›´æ¥å¸¦ç»™äººä»¬ã€‚æˆ‘å’Œä¸€ä¸ªçˆ±å›½è€…è½¦é˜Ÿä¼šåˆï¼Œæˆ‘ä»¬æŠŠç‰©èµ„è¿åˆ°äººä»¬æ— æ³•åˆ°è¾¾çš„åœ°æ–¹ï¼Œä»¥åŠé“è·¯å°é—­çš„åœ°æ–¹ã€‚æˆ‘å¼€ç€å¡è½¦åˆ°å¤„è·‘ï¼Œä»–ä»¬ä¹Ÿå¼€ç€å¡è½¦åˆ°å¤„è·‘ã€‚â€<!-- raw HTML omitted -->ğŸ”»â€”â€”â€œ can&rsquo;t believe what I saw today. I&rsquo;ve been out for 12 hours bringing supplies to people up in the mountains. I was in Yancey County, Mitchell County, Bakersville, Spruce Pine, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA2XNvRRl">ğŸ”»[å¾®ç¬‘]ğŸ”»åªæœ‰åœ¨æˆ‘ä»¬è¿™ä½ æ‰èƒ½çœ‹åˆ°è¿™ä¸ªã€‚ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa2xnvrrl/">
    
    
    
    
    
      
    
    ğŸ”»<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ğŸ”»åªæœ‰åœ¨æˆ‘ä»¬è¿™ä½ æ‰èƒ½çœ‹åˆ°è¿™ä¸ªã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sin">https://tvax1.sin</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA2yYl3TB">è¿™äººå¹²å•¥çš„ï¼Ÿ//@zfdgifjsjxf:ç§¦éœ„è´¤è¢«çˆ†ç“œï¼Œç„¶åä»–å®¶ä¼ªé€ äº†ä¸€ç¯‡äººæ°‘ç½‘çš„æ–°é—»ç¨¿æŠ¹é»‘å¯¹æ–¹ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»è¿™ä»€ä¹ˆç“œï¼Ÿ#å‡å†’åª’ä½“å²‚æ˜¯å„¿æˆ#</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa2yyl3tb/">
    
    
    
    
    
      
    
    è¿™äººå¹²å•¥çš„ï¼Ÿ//<!-- raw HTML omitted -->@zfdgifjsjxf<!-- raw HTML omitted -->:ç§¦éœ„è´¤è¢«çˆ†ç“œï¼Œç„¶åä»–å®¶ä¼ªé€ äº†ä¸€ç¯‡äººæ°‘ç½‘çš„æ–°é—»ç¨¿æŠ¹é»‘å¯¹æ–¹<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»è¿™ä»€ä¹ˆç“œï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å‡å†’åª’ä½“å²‚æ˜¯å„¿æˆ#<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA3748bZS">ğŸ”»å…³äºè¿™è´´ï¼Œæœ‰å¾ˆå¤šæˆ‘ä»¬çš„ç½‘å‹è®¤ä¸ºâ€œä¸€ä¸ªå®¶åº­æ€ä¹ˆå¯èƒ½ç”¨è¿™ä¹ˆå¤šç”µâ€ã€‚ğŸ”»è¿™é‡Œæœ‰@åä¹‰å‡› çš„ç§‘æ™®è´´ ç½‘é¡µé“¾æ¥ ç½‘é¡µé“¾æ¥ ç½‘é¡µé“¾æ¥ğŸ”»ç®€å•çš„è¯´ï¼Œå°±æ˜¯ä»è¾“ç”µçº¿è·¯ã€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa3748bzs/">
    
    
    
    
    
      
    
    ğŸ”»å…³äºè¿™è´´ï¼Œæœ‰å¾ˆå¤šæˆ‘ä»¬çš„ç½‘å‹è®¤ä¸ºâ€œä¸€ä¸ªå®¶åº­æ€ä¹ˆå¯èƒ½ç”¨è¿™ä¹ˆå¤šç”µâ€ã€‚<!-- raw HTML omitted -->ğŸ”»è¿™é‡Œæœ‰<!-- raw HTML omitted -->@åä¹‰å‡›<!-- raw HTML omitted --> çš„ç§‘æ™®è´´ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç½‘é¡µé“¾æ¥<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/">https://h5.sinaimg.cn/</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA37tDl6Y">ğŸ”»ä½†æ˜¯å·¦è¾¹æ”¯æŒå·´å‹’æ–¯å¦ï¼Œå³è¾¹å‰ä»¥å†›ã€æ”¯æŒä»¥è‰²åˆ—ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa37tdl6y/">
    
    
    
    
    
      
    
    ğŸ”»ä½†æ˜¯å·¦è¾¹æ”¯æŒå·´å‹’æ–¯å¦ï¼Œå³è¾¹å‰ä»¥å†›ã€æ”¯æŒä»¥è‰²åˆ—ã€‚ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA3cu7LzG">6//@ä¸€è¡Œæ³•å¸ˆ:ä½†æ˜¯å·¦è¾¹æ­§è§†äºšè£”/ä¹³åŒ–[doge]å®Œç¾å¯¹å†²äº† - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»ä½†æ˜¯å·¦è¾¹æ”¯æŒå·´å‹’æ–¯å¦ï¼Œå³è¾¹å‰ä»¥å†›ã€æ”¯æŒä»¥è‰²åˆ—ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa3cu7lzg/">
    
    
    
    
    
      
    
    6//<!-- raw HTML omitted -->@ä¸€è¡Œæ³•å¸ˆ<!-- raw HTML omitted -->:ä½†æ˜¯å·¦è¾¹æ­§è§†äºšè£”/ä¹³åŒ–<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å®Œç¾å¯¹å†²äº†<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»ä½†æ˜¯å·¦è¾¹æ”¯æŒå·´å‹’æ–¯å¦ï¼Œå³è¾¹å‰ä»¥å†›ã€æ”¯æŒä»¥è‰²åˆ—ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OA3wRBShV">ğŸ”»è¿™ä¸ªæœˆçš„WOWå•†æ ˆå¹»åŒ–çœŸåŠ²å•Šã€‚ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oa3wrbshv/">
    
    
    
    
    
      
    
    ğŸ”»è¿™ä¸ªæœˆçš„WOWå•†æ ˆå¹»åŒ–çœŸåŠ²å•Šã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0F1aWVz">ç­‰å›å»åä¸€å®šä¹°ä¸ªç”Ÿå†™æ¶å­ï¼ˆ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0f1awvz/">
    
    
    
    
    
      
    
    ç­‰å›å»åä¸€å®šä¹°ä¸ªç”Ÿå†™æ¶å­ï¼ˆ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0g3mw1t">å¥½æƒ³åƒç‚¸é¸¡</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0g3mw1t/">
    
    
    
    
    
      
    
    å¥½æƒ³åƒç‚¸é¸¡  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0GBxBGa">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ via.ç·’è¡Œè®°fb&amp;ins [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0gbxbga/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ç·’è¡Œè®°fb&amp;ins &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/006z6nxLgy1huajag3kunj30u00j7q4l.jpg%22">https://tvax2.sinaimg.cn/large/006z6nxLgy1huajag3kunj30u00j7q4l.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0GK1mj6">èƒŒå½±å¼å¼çœ‹ğŸ¥¹ - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ via.ä¹ƒæœ¨å‚46 ins [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0gk1mj6/">
    
    
    
    
    
      
    
    èƒŒå½±å¼å¼çœ‹ğŸ¥¹<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ä¹ƒæœ¨å‚46 ins &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/006z6nxLgy1huajcbj8tmj3140140jwm.jpg%22">https://tvax2.sinaimg.cn/large/006z6nxLgy1huajcbj8tmj3140140jwm.jpg&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0GY5H40">æˆ‘å‹’ä¸ªé‚¦é‚¦ï¼Œå¥½å°ä¼—çš„æ´» - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# 10/14 æ˜ŸæœŸä¸€ä¸‹åˆ2ç‚¹å¼€å§‹åœ¨Eé¢‘é“ç›´æ’­ã€ç¬¬91å±ŠNHKå…¨å›½å­¦æ ¡éŸ³ä¹åˆå”±æ¯”èµ›ã€æˆ‘å°†æ‹…ä»»åˆä¸­...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0gy5h40/">
    
    
    
    
    
      
    
    æˆ‘å‹’ä¸ªé‚¦é‚¦ï¼Œå¥½å°ä¼—çš„æ´»<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid">https://m.weibo.cn/search?containerid</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0H146Dg">æ€¥æ€¥æ€¥ - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# è¢«æœªæ¥çš„æˆ‘æš´å‡»ï¼ï¼Ÿå…¬å¸ƒäº†äººç‰©å…³ç³»å›¾è·ç¦»æ’­å‡ºè¿˜æœ‰3å¤©..ï¼å¥½æœŸå¾…å¥½æœŸå¾…æ‹æ‘„ç°åœºåˆ°å¤„é£˜è¡ç€â€œæš´å‡»æš´å‡»ï½...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0h146dg/">
    
    
    
    
    
      
    
    æ€¥æ€¥æ€¥<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiori">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiori</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA0Kbc1ei">å¥½å¥½å¥½ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa0kbc1ei/">
    
    
    
    
    
      
    
    å¥½å¥½å¥½ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OA55m1cFg">å¥½é™©ï¼å·®ç‚¹å°±ä¸­æ–‡å¤¹è‹±æ–‡äº†[å‰‘ç½‘3]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-oa55m1cfg/">
    
    
    
    
    
      
    
    å¥½é™©ï¼å·®ç‚¹å°±ä¸­æ–‡å¤¹è‹±æ–‡äº†[å‰‘ç½‘3]  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OzYEgmSGh">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.10.04 10:54ã€Œå•Šãƒ¼ã€æ—©ä¸Šå¥½å“¦æœ€è¿‘å›è¿‡ç¥æ¥å°±è¿‡äº†å¥½äº›æ—¥å­å¿…é¡»å¥½å¥½ç”Ÿæ´»æƒ³çœ‹çš„ç”µå½±å¤ªå¤šäº†æ€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ozyegmsgh/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%253">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OzYlgjI8e">å¥½æƒ³åƒè›™</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ozylgji8e/">
    
    
    
    
    
      
    
    å¥½æƒ³åƒè›™  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OA05UDvFC">åˆ†äº«å›¾ç‰‡ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-oa05udvfc/">
    
    
    
    
    
      
    
    åˆ†äº«å›¾ç‰‡ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OA0E8c8Ev">è½‰ç™¼å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ via.ç·’è¡Œè®°fb&amp;ins [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-oa0e8c8ev/">
    
    
    
    
    
      
    
    è½‰ç™¼å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ç·’è¡Œè®°fb&amp;ins &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/006z6nxLgy1huajag3kunj30u00j7q4l.jpg%22">https://tvax2.sinaimg.cn/large/006z6nxLgy1huajag3kunj30u00j7q4l.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OA0Hm2V7A">çˆ†æ“Šï¼Ÿï¼ - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# è¢«æœªæ¥çš„æˆ‘æš´å‡»ï¼ï¼Ÿå…¬å¸ƒäº†äººç‰©å…³ç³»å›¾è·ç¦»æ’­å‡ºè¿˜æœ‰3å¤©..ï¼å¥½æœŸå¾…å¥½æœŸå¾…æ‹æ‘„ç°åœºåˆ°å¤„é£˜è¡ç€â€œæš´å‡»æš´å‡»...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-oa0hm2v7a/">
    
    
    
    
    
      
    
    çˆ†æ“Šï¼Ÿï¼<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shior">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shior</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OA0KnznEN">è½‰ç™¼å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# 10/14 æ˜ŸæœŸä¸€ä¸‹åˆ2ç‚¹å¼€å§‹åœ¨Eé¢‘é“ç›´æ’­ã€ç¬¬91å±ŠNHKå…¨å›½å­¦æ ¡éŸ³ä¹åˆå”±æ¯”èµ›ã€æˆ‘å°†æ‹…ä»»åˆä¸­ç»„çš„å˜‰å®¾ä¸»æŒã€‚...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-oa0knznen/">
    
    
    
    
    
      
    
    è½‰ç™¼å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522typ">https://m.weibo.cn/search?containerid=231522typ</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OA1NN6DGk">é€£èƒŒå½±éƒ½å¥½çœ‹[å“‡] - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ via.ä¹ƒæœ¨å‚46 ins [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-oa1nn6dgk/">
    
    
    
    
    
      
    
    é€£èƒŒå½±éƒ½å¥½çœ‹<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_defa">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_defa</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OA0CbDpn0">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# 10/14 æ˜ŸæœŸä¸€ä¸‹åˆ2ç‚¹å¼€å§‹åœ¨Eé¢‘é“ç›´æ’­ã€ç¬¬91å±ŠNHKå…¨å›½å­¦æ ¡éŸ³ä¹åˆå”±æ¯”èµ›ã€æˆ‘å°†æ‹…ä»»åˆä¸­ç»„çš„å˜‰å®¾ä¸»æŒã€‚èƒ½æ‹…ä»»ä¸€ç›´æ˜¯æ¢¦å¯ä»¥æ±‚çš„n conçš„ä¸»æŒ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oa0cbdpn0/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OA0FdzqU1">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# è¢«æœªæ¥çš„æˆ‘æš´å‡»ï¼ï¼Ÿå…¬å¸ƒäº†äººç‰©å…³ç³»å›¾è·ç¦»æ’­å‡ºè¿˜æœ‰3å¤©..ï¼å¥½æœŸå¾…å¥½æœŸå¾…æ‹æ‘„ç°åœºåˆ°å¤„é£˜è¡ç€â€œæš´å‡»æš´å‡»ï½â€çš„å£°éŸ³ã€‚#æš´å‡»# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oa0fdzqu1/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram#&lt;/span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OA0wQi7Fa">ä¹…ä¿å²ç»ªé‡Œ via.ç·’è¡Œè®°fb&amp;ins [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oa0wqi7fa/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ç·’è¡Œè®°fb&amp;ins <!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/006z6nxLgy1huajagi2ttj">https://tvax3.sinaimg.cn/large/006z6nxLgy1huajagi2ttj</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OA0xCAKQX">ä¹…ä¿å²ç»ªé‡Œ via.ä¹ƒæœ¨å‚46 ins [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oa0xcakqx/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ä¹ƒæœ¨å‚46 ins <!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1huajcbz3ajj31">https://tvax1.sinaimg.cn/large/006z6nxLgy1huajcbz3ajj31</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OzXFe28eh">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.10.04 10:54ã€Œå•Šãƒ¼ã€æ—©ä¸Šå¥½å“¦æœ€è¿‘å›è¿‡ç¥æ¥å°±è¿‡äº†å¥½äº›æ—¥å­å¿…é¡»å¥½å¥½ç”Ÿæ´»æƒ³çœ‹çš„ç”µå½±å¤ªå¤šäº†æ€ä¹ˆåŠï¼Œçœ‹äº†ä¸€ç›´åœ¨çœ‹ç”µè§†å‰§çš„å¤§ç»“å±€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-ozxfe28eh/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23</a>&amp; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.gimp.org/news/2024/10/05/development-update/">Development Update: Closing In on the 3.0 ReleaseÂ Candidate</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-04</span>
  </div>
  <div class="summary">
    <a href="/post/www-gimp-org-news-2024-10-05-development-update/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

